Search Results
Your search for The%20,The matches 7896 pages
Showing 101 - 150FANSS: Should Lung Cancer Screening Guidelines Be Expanded to Include Female Asian Nonsmokers?
The results of the multicenter Female Asian Nonsmoker Screening Study (FANSS) suggest that low-dose CT screening is feasible and has value for early lung cancer detection in the historically underserved demographic of Asian women with no history of smoking. These data from the largest United...
Improved Outcomes Reported With Second-Line Regimen of Ivonescimab Plus Chemotherapy in NSCLC
In the phase III HARMONi trial, when ivonescimab was given with carboplatin plus pemetrexed, vs the chemotherapy regimen alone, after a third-generation tyrosine kinase inhibitor, patients with EGFR-mutated non–small cell lung cancer (NSCLC) had a significant delay in disease progression.1...
Pulsed Low-Dose–Rate Chemoradiation Reduces Severe Esophagitis in Esophageal Cancer and NSCLC
Chemoradiation with a pulsed low-dose–rate technique led to lower-than-usual rates of severe esophagitis without compromising efficacy in patients with esophageal and non–small cell lung cancer (NSCLC), according to findings from a single-arm phase I study presented as a poster during the American...
Predicting Future Breast Cancer Outcomes: Efficacy of a Polygenic Risk Score
Studies show that if left untreated, between 20% and 40% of ductal carcinoma in situ (DCIS) lesions may evolve into invasive breast cancer over time. And, according to the American Cancer Society, women diagnosed with lobular carcinoma in situ (LCIS) have between a 7 and 12 times higher risk of...
Immunogenicity of RSV Vaccines in Immunocompromised Allogeneic HSCT Recipients
In patients rendered immunocompromised by allogeneic hematopoietic stem cell transplantation (HSCT), a single dose of the respiratory syncytial virus (RSV) vaccine within the first year afterward resulted in low seroconversion rates, as reported by Redjoul et al in JAMA Network Open. However, a...
Dexamethasone-Sparing Regimen for Frail Patients With Newly Diagnosed Multiple Myeloma
In a French phase III trial (IFM2017-03) reported in The Lancet Oncology, Manier et al found that a dexamethasone-sparing regimen of daratumumab plus lenalidomide improved progression-free survival vs lenalidomide plus dexamethasone in patients with frailty and newly diagnosed multiple myeloma....
CD19 CAR T-Cell Therapy May Be Effective in Treating Resistant Ulcerative Colitis
Studies show that individuals diagnosed with ulcerative colitis have approximately a twofold increased risk of developing colorectal cancer compared with the general population. A study investigating treatment with autologous chimeric antigen receptor (CAR) T cells targeting the CD19 antigen in a...
Sunvozertinib in Platinum-Pretreated NSCLC With EGFR Exon 20 Insertion Mutations
In a phase II trial (WU-KONG1B) reported in the Journal of Clinical Oncology, Yang et al found that the EGFR tyrosine kinase inhibitor sunvozertinib was active at both dose levels tested in patients with platinum-pretreated non–small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations....
Intermediate-Risk Prostate Cancer: Shorter Radiation Improves Patient Experience, But Not Disease Control
For patients with intermediate-risk, localized prostate cancer, radiation therapy delivered in five sessions reduced patient-reported side effects compared to longer courses of radiation, according to results of a large, randomized phase III trial. Patients treated with stereotactic body radiation...
Oropharyngeal Cancer Quality-of-Life Outcomes: IMRT vs Proton-Beam Therapy
A new phase III clinical trial has found that intensity-modulated radiation therapy (IMRT) and proton-beam therapy resulted in similar quality-of-life outcomes and low rates of side effects for people with locally advanced oropharyngeal cancer. The TORPEdO trial, a randomized study conducted across ...
Adjuvant Radiation Therapy Safe and Beneficial in Locally Advanced Muscle-Invasive Bladder Cancer
Adjuvant radiation therapy following radical cystectomy and chemotherapy was found to be safe and efficacious for patients with locally advanced muscle-invasive bladder cancer, according to findings from the phase III randomized BART trial presented at the American Society for Radiation Oncology...
Modified FOLFIRINOX vs Gemcitabine/Nab-Paclitaxel in Metastatic Pancreatic Cancer
In a phase II trial (PASS-01) reported in the Journal of Clinical Oncology, Knox et al found similar progression-free survival with modified leucovorin, fluorouracil, irinotecan, oxaliplatin (mFOLFIRINOX) vs gemcitabine/nab-paclitaxel in patients with previously untreated metastatic pancreatic...
Localized PI3K-Altered Colorectal Cancer: Does Low-Dose Aspirin Reduce the Risk of Recurrence?
In a Scandinavian trial (ALASCCA) reported in The New England Journal of Medicine, Martling et al found that low-dose aspirin reduced the risk of disease recurrence vs placebo in patients with PI3K-altered localized colorectal cancer. Study Details In the double-blind trial, patients with stage I...
Zidesamtinib Shows Activity in Pretreated and Tyrosine Kinase Inhibitor–Naive Patients With ROS1-Positive NSCLC
Zidesamtinib, an investigational oral, highly selective ROS1 tyrosine kinase inhibitor designed to overcome common resistance mechanisms and improve brain penetration, has demonstrated activity in both pretreated and tyrosine kinase inhibitor–naive patients with ROS1-positive non–small cell lung...
Neoadjuvant FOLFIRINOX vs Gemcitabine-Based Chemoradiotherapy in Pancreatic Ductal Adenocarcinoma
In a Dutch phase III trial (PREOPANC-2) reported in The Lancet Oncology, Janssen et al found no difference in overall survival between patients receiving neoadjuvant FOLFIRINOX vs neoadjuvant gemcitabine-based chemoradiotherapy for resectable or borderline resectable pancreatic ductal...
Clonal Hematopoiesis
The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that quizzes readers on issues in hematology. In this installment, Syed Ali Abutalib, MD, and L. Jeffrey Medeiros, MD, focuses on clonal hematopoiesis of indeterminate potential (also referred to as CHIP) as well as...
Medical Imaging and Risk of Pediatric and Adolescent Hematologic Cancer
In a study reported in The New England Journal of Medicine, Smith-Bindman et al found that medical imaging among children was associated with a significantly increased risk of pediatric and adolescent hematologic cancer. The study involved data from a retrospective cohort of 3,724,623 children born ...
ASCO Remembers Past President Harvey M. Golomb, MD, FASCO
ASCO is deeply saddened by the loss of past president Harvey M. Golomb, MD, FASCO, a pioneer in the study of interferon as cancer treatment. Dr. Golomb passed away on August 20, 2025; he was 82. From the beginning of his medical career, Dr. Golomb was a committed member of ASCO. He joined the...
AACR Cancer Progress Report 2025 Highlights Breakthroughs in Blood Cancers and How NIH Funding Uncertainty Threatens Advances
The 15th edition of the annual AACR Cancer Progress Report presents a mixed picture of the major advances in cancer care over the past year, including the approval of 20 new anticancer drugs, juxtaposed against the continuing rise in early-onset cancers and disparities in care as well as the...
Overall Survival Benefit Shown for Neoadjuvant Nivolumab Plus Chemotherapy in Non–Small Cell Lung Cancer
In the preplanned final analysis of the phase III CheckMate 816 trial, an overall survival benefit has been shown for neoadjuvant nivolumab plus chemotherapy in patients with resectable non–small cell lung cancer (NSCLC).1 Patients treated with the combination experienced an approximate 10%...
New Approvals for Thrombocytopenia, Lung Cancer, Brain Cancer, and Multiple Myeloma
BTK Inhibitor for Chronic Immune Thrombocytopenia: On September 2, 2025, the U.S. Food and Drug Administration (FDA) approved the Bruton’s tyrosine kinase (BTK) inhibitor rilzabrutinib (Wayrilz) tablets to treat adults with persistent or chronic immune thrombocytopenia (ITP) who have had an...
Tislelizumab-Based Triplet Therapy for Conversion of Unresectable to Resectable Locally Advanced Biliary Tract Cancer
In a Chinese phase II trial (ZSAB-TransGOLP) reported in The Lancet Oncology, Shi et al found promising results with tislelizumab plus lenvatinib and GEMOX (gemcitabine plus oxaliplatin) chemotherapy (GOLP) in converting unresectable locally advanced biliary tract cancer to resectable disease....
Cardiotoxicity From the Use of Anthracyclines in Cancer Survivors: Preventive Strategies
Many patients from Europe and the United States have experienced the benefits of anthracyclines in the treatment of an array of cancers, including solid tumors such as breast and ovarian cancers as well as lymphoma. However, a number of these cancer survivors will experience severe chronic cardiac...
Bridging the Gap in Geriatric Oncology Education: A Global Imperative
As the global population ages, oncology faces an urgent challenge: ensuring that health-care professionals are adequately trained to address the unique complexities of cancer care for older adults. Despite the increasing prevalence of cancer in this demographic, geriatric oncology education remains ...
Overcoming the Challenges of Safely Using Opioids to Treat Patients With Chronic Cancer-Related Pain
Research has shown that pain is among the most commonly experienced and feared aspects of a cancer diagnosis.1 It’s easy to understand why. In fact, cancer-related pain is so ubiquitous, between 20% and 50% of patients with early-stage cancer will experience pain,2 and up to 90% of patients with...
Update to ASCO Living Guideline for NSCLC Without Driver Alterations Includes First Comparison of Immunotherapy Options
ASCO has issued a new update to its living guideline regarding therapy for stage IV non–small cell lung cancer (NSCLC) without driver alterations, based on results of three studies published recently.1 The update (the first since a previous version in February 2025) includes discussion of...
Aumolertinib Plus Chemotherapy Improves PFS in NSCLC With EGFR and Concomitant Tumor Suppressor Genes
New results from the phase III ACROSS 2 trial demonstrated that aumolertinib, an oral third-generation EGFR tyrosine kinase inhibitor (TKI), combined with platinum-pemetrexed chemotherapy significantly improved progression-free survival (PFS) compared with aumolertinib monotherapy in patients with...
Living With the Real-World Consequences of Federal Budget Cuts on Cancer Research
The outlook for adequate funding for federal health agencies has become more dire. In July, the National Cancer Institute (NCI) announced it is reducing the number of grant applications it will award for the remaining 2 months of fiscal year 2025 (FY2025), from 9% down to 4%.1 The result is that...
Zidesamtinib Demonstrates Responses in ROS1-Positive NSCLC
Treatment with the next-generation ROS1 tyrosine kinase inhibitor (TKI) zidesamtinib led to antitumor activity in patients with ROS1-positive non‒small cell lung cancer (NSCLC) who had experienced disease progression on prior TKI treatments. These findings from the phase I/II ARROS-1 trial were...
A Year of Global Progress Against Cancer—and Persistent Challenges
Despite data from the latest edition of The Cancer Atlas showing that nearly half of cancer mortality worldwide is attributed to modifiable risk factors, cancer incidence and mortality rates continue to soar.1 Globally, approximately 19 million new cases of cancer, excluding nonmelanoma skin...
New Report on Breast Reconstruction Preferences Among African American Women
For African American patients undergoing mastectomy, the risk of complications and the postoperative appearance of the breast are among the important drivers of preferences about breast reconstruction, according to a new report published by Shammas et al in Plastic and Reconstructive Surgery....
Study Shows That After Early Breast Cancer Diagnosis, Risk of a Second Cancer Is Low
For individuals diagnosed with early breast cancer, the long-term risk of developing a second primary cancer is low—around 2% to 3% greater than the general population)—according to findings published by McGale et al in The BMJ. The researchers say this information can help reassure many breast...
Understanding Accelerated Aging in Survivors of Childhood Cancers
Each year in the United States, nearly 16,000 children and adolescents between the ages of birth and 19 are diagnosed with cancer.1 And although survival rates have greatly improved for many types of childhood cancers, with more than 8 in 10 children and adolescents surviving at least 5 years after ...
Real-World Incidence and Management of Infusion-Related Reactions to Monoclonal Antibody Therapy
In a retrospective analysis published in JCO Oncology Practice, Smolders et al investigated the incidence and clinical course of infusion-related reactions among patients treated with at least one monoclonal antibody in routine practice. The study evaluated real-world data to compare observed...
Disparities in U.S. County–Level Cervical Cancer Screening Coverage Lead to Differences in Outcomes
In a study reported as a research letter in JAMA Network Open, Amboree identified U.S. counties with low or high cervical cancer screening coverage and associated risks of cervical cancer incidence and mortality. As stated by the investigators, “Recent research shows that cervical cancer incidence...
Factors Influencing Symptom Burden in Pediatric Patients With Cancer: Insights From Routine Screening
As pediatric cancer survival rates continue to improve, attention has shifted to quality of life and symptom management. While a majority of patients experience problematic symptoms during treatment, these symptoms usually go undocumented and untreated. In a secondary analysis of a cluster...
Study Finds Weather Disasters Increase Risk for U.S. Drug Supply Chain Disruption
In 2024, Hurricane Helene triggered a nationwide shortage of the country’s intravenous (IV) fluids after damaging a facility in North Carolina. A similar IV fluid shortage was caused when Hurricane Maria hit Puerto Rico in 2017. In a recent, nationwide study led by the American Cancer Society...
Smoldering Multiple Myeloma: How the Guidance Is Changing
Clinical trials have sought to determine the benefit of treating the precursors of multiple myeloma, but as the phenotypes and genomics of this entity are becoming better delineated, the wisdom of early intervention has remained confusing for clinicians. At the 2025 Debates and Didactics in...
Advancing Geriatric Oncology: A Personal and Professional Journey
I would like to begin by sharing a bit of my journey in geriatric oncology. Often, we do not hear the origin stories behind our professional paths, and I believe it is important to reflect on them. I have spent my entire academic career at Wake Forest University School of Medicine, where I arrived...
Studies on EGFR Mutations and NRG1 Fusions Included in ASCO NSCLC Living Guideline Update
ASCO has issued a new update to its living guideline on treatment of stage IV non–small cell lung cancer (NSCLC) with driver alterations based on two recent studies.1 The update, which amends the most recent version published in February 2025, includes a discussion of osimertinib therapy options in ...
Routine AI Assistance May Lead to Loss of Skills in Endoscopists, Study Shows
The introduction of artificial intelligence (AI) to assist colonoscopies may be linked to a reduction in the ability of endoscopists to detect adenomas in the colon without AI assistance, according to a paper published by Budzyń et al in The Lancet Gastroenterology & Hepatology. Colonoscopy...
Best of ASCO 20th Anniversary: Advancing Medicine and Patient Care, ASCO Style!
For the 20th year in a row, major advances in cancer research and practice-changing clinical trials from the 2025 ASCO Annual Meeting (ASCO25) were presented at the ASCO-licensed Best of ASCO meeting, held on July 18–19, 2025, in Beirut, Lebanon. It was indeed a great celebration and commitment to...
Can Baseline PSMA-PET Help to Predict Response to LuPSMA and Enzalutamide in mCRPC?
In a substudy of the Australian phase II ENZA-p trial reported in The Lancet Oncology, Emmett et al found that baseline prostate-specific membrane antigen (PSMA)–positron-emission tomography (PET) total tumor volume (TTV) was prognostic for overall survival and predictive for a beneficial effect on ...
John C. Byrd, MD, FASCO, Named UPMC Hillman Cancer Center Director
John C. Byrd, MD, FASCO, an internationally lauded researcher and clinical specialist in hematologic malignancies, has been appointed Director of UPMC Hillman Cancer Center, effective November 2025. In his role as Director, Dr. Byrd will be responsible for all aspects of the University of...
Potential New Second-Line Standard of Care Emerges in Small Cell Lung Cancer
In patients with small cell lung cancer, second-line treatment with the bispecific T-cell engager tarlatamab-dlle (which targets the delta-like ligand 3 [DLL3]) vs standard-of-care chemotherapy appeared to significantly improve overall survival, progression-free survival, and patient-reported...
Two ACS Studies Show Colorectal Cancer Screening and Early Diagnosis Have Soared in Adults Aged 45 to 49 Years
It has been widely reported that colorectal cancer incidence has been increasing among younger adults under age 50 since the mid-1990s, with a consistent annual increase of 2% among adults aged 20 to 39. This increase prompted the American Cancer Society (ACS), in 2018, and the United States...
Investigating the Mechanisms of Cardiovascular Adverse Events Linked to Certain Cancer Treatments
The true upside of the many advances in cancer treatment is clear. Approximately 18.6 million people in the United States have a history of cancer, and the number of cancer survivors is expected to exceed 22 million by the year 2035.1However, one downside affecting many of these individuals is...
Immune Checkpoint Inhibitors, Cardiovascular Health, and a Potentially Protective Biomarker
New research out of Spain has shown that patients with cancer who had lower levels of the biomarker CD69 (receptor on T cells) before starting treatment with immune checkpoint inhibitors (ICIs) had a more negative immune response and were at higher risk of cardiovascular damage and myocarditis.1...
Use of Cemiplimab as Adjuvant Therapy for High-Risk Cutaneous Squamous Cell Carcinoma
The randomized phase III C-POST trial attempted to learn whether the standard-of-care treatment in advanced cutaneous squamous cell carcinoma—cemiplimab-rwlc, which blocks the PD-1/PD-L1 pathway—could reduce recurrence after definitive local therapy for patients who had high-risk features....
Acute Myeloid Leukemia With RUNX1::RUNX1T1 Fusion
The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that quizzes readers on issues in hematology. In this installment, Syed Ali Abutalib, MD, and L. Jeffrey Medeiros, MD, explore the impact of the prognostic marker RUNX1::RUX1T1 fusion on the diagnosis and treatment of...
